Print this page

Plant Grand Island, Melrose Park; USA

Key Data

Fresenius Kabi USA develops, manufactures and markets injectable pharmaceuticals, with important products in the oncology, anti-infective, anaesthetic / analgesic and critical care fields.


  1. Facilities:
    • Grand Island, NY

    • Melrose Park, IL

  2. Containers:

    • PFS: 1 and 5 ml

    • Plastic vials: 3, 10, 20, 30 & 50 ml

    • Glass vials: 2, 3, 5, 10, 20, 30, 50, 100, 125, & 200 ml

  3. Technologies:

    •  Lyophilization

    • Aseptic liquid filling

    • Aseptic SCF syringes

    • Terminal sterilization

  4. Certifications:

    • US-FDA

  5. Batch-Sizes:

    •  PFS: max. 30 L

    • Plastic Vials: max. 1.800 L

    • Glass Vials: max. 2.000 L

  6. Services:

    • QC Support

    • Secondary Packaging

    • Stability Studies

    • Warehousing & Shipping

    • Regulatory Support


In the Spotlight

The acquisition of APP in 2008 has given Fresenius Kabi an entry into the U.S. pharmaceutical market and a leading position in the global I.V. generics industry. The company offers one of the most comprehensive portfolios of products used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a complete range of dosage formulations.


Integrating the APP plants into the Fresenius Kabi global production network means that the group now has a presence with substantial manufacturing expertise and technical capabilities in North America.

 Fresenius Kabi USA operates out of two sites, located in upstate New York and Illinois.


The Grand Island facility is located just a few minutes from the spectacular Niagara Falls, near Buffalo. The site employs approximately 600 people in three buildings. The main building houses aseptic wash and fill (terminal sterilization) manufacturing processes. In the other buildings are offices, laboratories, the warehouse, and a new manufacturing area, with some space for expansion.  


Another site is located in Melrose Park, Illinois, on the outskirts of Chicago and just 5 miles from O`Hare International Airport. The plant is in a general industrial area and employs approximately 700 people. Besides production, laboratory, office and warehouse facilities the plant also has a state-of-the-art microbiology laboratory, opened in November 2009.  

With the APP platform, Fresenius Kabi is able to market its entire product range in the US, and furthermore through its international marketing and sales network to sell APPs products globally. But the acquisition has not only enlarged Fresenius Kabi‘s internal capabilities – it has also broadened the possibilities and capabilities of Fresenius Kabi Product Partnering. All the technological capabilities of the APP division (see key facts) are also available for external customers, depending on capacity.